The value of suPAR for the Clinician

With the suPARnostic® prognosis for risk of disease progression there is now a reliable tool to aid in prioritizing patients in the Emergency Department. Numerous publications have confirmed suPARnostic® as a novel marker for risk prediction and emergency departments are starting to implement this novel concept for risk stratification.

Identifying a patient’s suPARnostic® level upon presentation to hospitals or clinics will enable clinicians to assess which patients require immediate attention and further testing in order to ensure timely treatment.

MD, Assistant Professor, Harvard Medical School, ER, Beth Israel Deaconess Medical Center, Boston:
“If test results such as lab data and imaging data are immediately available…, hospital staff will win valuable time, which can improve patient flow and ultimately save lives”

MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen:
“The key challenge for the ER is to indentify the ill patients faster, make diagnosis faster, find the right specialist faster and initiate the right treatment faster”

The suPAR level is associated withpresence, severity and progression of disease, and in unselected patients, suPAR is one of the strongest prognostic biomarkers available to date. 

On the basis of more than 600 published articles on suPAR in PubMed, a suPAR Monograph has been written.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas, and see how the suPAR level is affected within each kind of disease.

Please find the suPAR Monograph here:

suPAR Monograph (English)

suPAR Monograph (Spanish)

The benefits of the suPARnostic® test in the Emergency Department are :

  • Gives a faster result than any of the risk scores currently in use – because it is a quick biomarker test
  • Adds information – to allow the clinician to prioritize patients risk of disease progression
  • Simplifies procedures – because it is easy and simple to use

suPAR can improve patient triage in the Emergency Department

suPAR is in routine use in the Emergency Department at Copenhagen University Hospital Hvidovre, Denmark.

“The suPAR level can give an indication of whether the patient suffers from a severe disease and what the prognosis of the patient is….. is the patient severely ill?”

See the interview with the Head of the Emergency Department at Hvidovre Hospital and hear why they use the biomarker suPAR in routine use at the hospital.

For more information please also read:

Using suPAR as a Clinical Aid

suPARnostic® Risk Scale

suPARnostic® Test Options

suPAR biomarker and biology

suPAR is proposed as a robust and reliable prognostic tool for patient risk of disease progression.
suPAR was shown to be a potential assessment tool in the Emgergency Department [Uusitalo Seppälä et al., 2012, Koch A & Tacke F, 2012; Haupt T. et al., 2012] in addition to earlier studies demonstrating its value within critical care [Kofoed et al., 2006].
This is of clear importance aseconomic as well as patient survival considerations are calling for better tools toevaluate the state of patients upon hospital admission.

You may have experienced that one of your patients have had a suPAR test done when they went to the nearby emergency department or you may have seen it in the menu selection of your local laboratory. Here you can find more information about the suPAR biomarker and the suPARnostic® test with the suPARnostic® Risk Scale, and how this faster can identify patients with a higher risk of disease progression.

suPAR biomarker and biology

suPARnostic® Risk Scale

suPARnostic® Test Options

suPARnostic® as a predictor of lifestyle related events

For lifestyle related events several published studies show that:

  • Elevated suPARnostic® levels prognosticate an underlying health problem
  • Lifestyle impacts the suPARnostic® level
  • Without intervention individuals with high suPAR levels are at high risk of developing cardiovascular diseases, type-2 diabetes, cancer etc.

Read more about suPARnostic® as a predictor of lifestyle related events

The suPAR level is associated with presence, severity and progression of disease, and in unselected patients, suPAR is one of the strongest prognostic biomarkers available to date.

On the basis of more than 600 published articles on suPAR in PubMed, a suPAR Monograph has been written.
Here you can find a short summary of the research done on suPAR within 12 groups of disease areas, and see how the suPAR level is affected within each kind of disease.

Please find the suPAR Monograph here:

suPAR Monograph (English)

suPAR Monograph (Spanish)

In 2010 the MONICA 10 study, which included 2602 individuals aged 41, 51, 61or 71 years was published. Elevated baseline suPAR level was associated with an increased risk of cancer, CVD, T2D and mortality during follow-up. suPAR was more strongly associated with cancer, CVD and mortality in men than in women, and in younger compared with older individuals.
suPAR remained significantly associated with the risk of negative outcome after adjustment for a number of relevant risk factors including C-reactive protein levels.


Figure 1. Kaplan–Meier plot showing age-specific suPAR quartiles and CVD incidence. For each age group (41, 51, 61 and 71 years), suPAR was divided into quartiles. The darkest grey line (1. suPARquartile) refers to individuals with suPAR in the lowest quartile (0–25%). Similarly, the lightest grey line (4. suPARquartile) refers to individuals with the highest suPAR level (75–100%) [1].
1: Eugen-Olsen J. et al., Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population, J Intern Med. 2010 Sep;268(3):296-308.

So there is a clear clinical challenge in identifying the risk signals in due time to be able to